Why Farbe Firma is the Top Manufacturer of Meloxicam Injection
- Maulik Sudani
- 8 hours ago
- 8 min read
Last Updated: June 28, 2026
TL;DR: Meloxicam Injection - a sterile, clear yellow aqueous solution of meloxicam, an enolic-acid oxicam NSAID with preferential COX-2 activity, solubilised with meglumine and supplied commonly as a 15 mg/1.5 mL ampoule (10 mg/mL) given by deep intramuscular injection - is the once-daily, strong non-opioid anti-inflammatory clinicians use for the short-term symptomatic treatment of painful exacerbations of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis when an oral dose is not practical. Because meloxicam is a poorly water-soluble, light-sensitive active that has to be brought into solution with meglumine at a tightly controlled, slightly alkaline pH, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance profile, the meglumine-buffered pH that holds the active in solution, light protection, clarity and colour, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Meloxicam Injection at our Gujarat, India facility and supplies it to rheumatology, orthopaedic, pain-management and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Enolic-acid oxicam NSAID with preferential COX-2 activity - meloxicam inhibits prostaglandin synthesis with a relative preference for cyclo-oxygenase-2 to control pain and inflammation, and Meloxicam Injection (15 mg/1.5 mL, deep intramuscular) demands an exact, reproducible parenteral dose for the short-term symptomatic treatment of painful arthritic and musculoskeletal flares.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and ampoule filling lines, control of the stability-indicating assay, the related-substance profile, the meglumine content and tightly controlled slightly-alkaline pH that holds the poorly soluble active in solution, clarity and colour, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Meloxicam Injection Demands a Premium Manufacturer
Meloxicam Injection holds a familiar place in rheumatology, orthopaedic and pain-management practice across every market. It is the anti-inflammatory a clinician reaches for to start strong, once-daily symptom control when a patient is in the grip of a painful flare of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis and an oral dose is not practical - the first day or two of therapy before a patient settles onto tablets. What makes meloxicam distinctive among NSAIDs is its position on the selectivity spectrum: it is an enolic-acid oxicam with a relative, preferential affinity for cyclo-oxygenase-2 over cyclo-oxygenase-1, which is what underlies its once-daily profile and its place between the traditional non-selective NSAIDs and the fully selective coxibs. Because the injection is given parenterally, the dose from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Meloxicam Injection is presented as a ready-to-use sterile solution - for example 15 mg of meloxicam in a 1.5 mL ampoule, 10 mg/mL, given by deep intramuscular injection - so the assay must be exact and the fill volume accurate so that each unit delivers the labelled content. The defining formulation challenge is solubility: meloxicam is very poorly soluble in water, so it has to be brought into and held in solution using meglumine (N-methylglucamine) at a tightly controlled, slightly alkaline pH, which makes the meglumine content and the solution pH genuine critical quality attributes rather than incidental excipient details. The solution is characteristically clear and yellow, and that colour, along with freedom from visible and sub-visible particulates and low endotoxin, must be controlled; the manufacturer must run a stability-indicating method that resolves and quantifies meloxicam and its related substances without interference. Meloxicam is light-sensitive, so photostability under ICH Q1B and light-protective processing and amber-glass or otherwise light-resistant packaging matter, and the right sterilisation route - terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing - must be selected and validated. The class realities - that the classic intramuscular presentation is for deep intramuscular injection only and short-term initial use, together with the cardiovascular, gastrointestinal, renal and serious-skin-reaction cautions of the NSAID class - must be clearly reflected in the labelling. Choosing a Meloxicam Injection manufacturer that treats the stability-indicating assay, related-substance control, the meglumine-buffered pH that maintains solubility, photostability, and clarity and colour control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Meloxicam Injection Manufacturer Apart
A world-class manufacturer of Meloxicam Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of meloxicam with related-substance control by validated HPLC, which a potent oxicam NSAID demands; a robust, validated sterilisation and fill process built around a meglumine-solubilised solution that must stay clear, correctly coloured and precipitate-free from compounding through to the point of use; and tender-ready dossier support, including photostability and accelerated stability data, for an anti-inflammatory procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial-grade meloxicam sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the clarity, the colour and the solubility of a very poorly water-soluble active. The bulk solution is compounded in water-for-injection with meglumine at the tightly controlled, slightly alkaline pH that brings meloxicam into and holds it in solution, sterile-filtered through a 0.22 micron membrane and filled into ampoules - or vials - under ISO Class 5 conditions and under light protection, with the validated sterilisation route locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity, colour and particulate defects; in-process and release testing confirm the assay of meloxicam by validated HPLC, the related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular administration. Because the active is poorly soluble and light-sensitive and depends on meglumine to stay in solution, assay accuracy, related-substance control, meglumine-buffered-pH control and photostability are confirmed together so the assay, clarity and colour stay within specification across shelf life, with no precipitation in the ampoule.
Quality Systems Behind Every Meloxicam Injection
Every Farbe Firma Meloxicam Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of meloxicam against pharmacopoeial reference standards, control of related substances by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, light-protected compounding and holding, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because meloxicam is a poorly soluble, light-sensitive, meglumine-solubilised oxicam given parenterally and the assay, related-substance profile, meglumine-buffered pH and photostability drive both efficacy and safety, we treat the stability-indicating assay, the related-substance profile, the solubility-maintaining pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions, with ICH Q1B photostability documented, so the assay, clarity and colour stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Meloxicam Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad anti-inflammatory, rheumatology and peri-operative small-volume parenteral portfolio. For Meloxicam Injection specifically, we supply the ready-to-use 15 mg/1.5 mL solution in ampoule and vial presentations under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the stability-indicating-assay, related-substance, meglumine-and-pH, photostability, sterilisation and container-closure data package - ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork - including deep-intramuscular-only administration instructions, store-below-25-degrees-C and protect-from-light storage directions, and the cardiovascular, gastrointestinal, renal and serious-skin-reaction cautions - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Meloxicam Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the development of a stability-indicating assay for an oxicam NSAID, related-substance control, meglumine-solubilised controlled-pH formulation design, photostability strategy, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For an oxicam NSAID where dose precision, solubility control and clarity directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Meloxicam Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Meloxicam Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and ampoule filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Meloxicam Injection do you supply?
Our standard presentation is the ready-to-use 15 mg/1.5 mL (10 mg/mL) meglumine-solubilised solution of meloxicam in an ampoule for deep intramuscular injection. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Meloxicam Injection mainly used for?
Meloxicam Injection is used for the short-term symptomatic treatment of painful exacerbations of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis when an oral dose is not practical, typically as initial therapy. It is an enolic-acid oxicam NSAID with preferential COX-2 activity; Farbe Firma verifies the assay, related-substance profile, meglumine-buffered pH, clarity and colour, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose. The classic presentation is for deep intramuscular injection only, and the cardiovascular, gastrointestinal, renal and serious-skin-reaction cautions of the class are carried on the label.
Can Farbe Firma support country-specific registrations for Meloxicam Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Meloxicam Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our anti-inflammatory and rheumatology small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments